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Background: Hypertension is the leading global risk factor for mortality. Hypertension treatment and control rates
are low worldwide, and delays in seeking care are associated with increased mortality. Thus, a critical component of
hypertension management is to optimize linkage and retention to care.
Methods/Design: This study investigates whether community health workers, equipped with a tailored behavioral
communication strategy and smartphone technology, can increase linkage and retention of hypertensive
individuals to a hypertension care program and significantly reduce blood pressure among them. The study will be
conducted in the Kosirai and Turbo Divisions of western Kenya. An initial phase of qualitative inquiry will assess
facilitators and barriers of linkage and retention to care using a modified Health Belief Model as a conceptual
framework. Subsequently, we will conduct a cluster randomized controlled trial with three arms: 1) usual care
(community health workers with the standard level of hypertension care training); 2) community health workers
with an additional tailored behavioral communication strategy; and 3) community health workers with a tailored
behavioral communication strategy who are also equipped with smartphone technology. The co-primary outcome
measures are: 1) linkage to hypertension care, and 2) one-year change in systolic blood pressure among hypertensive
individuals. Cost-effectiveness analysis will be conducted in terms of costs per unit decrease in blood pressure and costs
per disability-adjusted life year gained.
Discussion: This study will provide evidence regarding the effectiveness and cost-effectiveness of strategies to optimize
linkage and retention to hypertension care that can be applicable to non-communicable disease management in
low- and middle-income countries.
Trial registration: This trial is registered with (NCT01844596) on 30 April 2013.
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Cardiovascular disease (CVD) is the leading cause of
mortality in the world, with 80% of CVD deaths occur-
ring in low- and middle-income countries (LMICs) [1].
Hypertension, a major risk factor for ischemic heart dis-
ease, heart failure, and stroke [2], is the leading global risk
for mortality [3]. The global cost of suboptimal blood
pressure (BP) is estimated to reach nearly $1 trillion over
the next decade [4]. Unless adequately controlled, hyper-
tension will continue to be responsible for significant mor-
bidity and mortality worldwide [5].
Rationale for a focus on linkage and retention to care
Hypertension awareness, treatment, and control rates
are low worldwide [6]. In Kenya, hypertension treatment
and control rates have been reported at below 15% and
5%, respectively [7-9]. Given that hypertension may be
asymptomatic, linkage and retention to care and medica-
tion adherence are particularly difficult challenges [10].
Delays in seeking hypertension care have been shown to
be associated with increased mortality [11]. Thus, early
linkage to hypertension care and successful retention to
clinical services are critical components of hypertension
management.
Studies of hypertension programs in sub-Saharan Africa
have suggested that addressing financial barriers, provider-
patient communication, and education may improve link-
age, retention, and medication adherence [12-14]. Although
preliminary qualitative research in western Kenya has re-
vealed that community members understand that hyperten-
sion can cause significant morbidity and mortality [15],
there are few known specific strategies to optimize linkage
and retention to hypertension care in this setting.
Components of the proposed intervention to optimize
linkage and retention to care
Community health workers (CHWs) are members of a
community who have received basic training to supply
community members with access to health and social ser-
vices, to educate individuals about various health issues,
and to support overall community development [16].
CHWs have been utilized in communicable disease and
maternal/child health programs [17]. However, they are
only recently being deployed and evaluated in the context
of non-communicable diseases [18], and the impact of
CHWs on linkage and retention to hypertension care in
Africa is relatively unknown.
Motivational interviewing and tailored communication-
strategies intended to tailor interventions based on individual-
specific behavioral assessments-have been shown to
improve a variety of health behaviors [19,20]. In addition,
mobile technology-based tools have the potential to
improve the scope and efficiency of CHWs, and have
demonstrated benefit for communicable diseases [21,22].However, these strategies have not been rigorously evalu-
ated in the context of hypertension management in
LMICs. Thus, we plan to utilize a multidisciplinary imple-
mentation research approach [23] to develop and evaluate
innovative community-based strategies, supported by mo-
bile technology, to optimize linkage and retention to a
hypertension management program in western Kenya.
Aims
The central hypothesis of this study is that CHWs equipped
with a tailored behavioral communication strategy, with
or without smartphone technology, can increase linkage
and retention of hypertensive individuals to a hyperten-
sion care program and thereby significantly reduce BP
among these patients, when compared to usual care. We
further hypothesize that these interventions will be cost-
effective. Thus, the aims of this study are threefold. First,
we aim to identify the facilitators and barriers to linking
and retaining individuals with high BP to a hypertension
care delivery program, using qualitative research methods.
With this information, we will develop a communication
strategy and a smartphone-based tool linked to an elec-
tronic health record. Second, we aim to evaluate the incre-
mental effectiveness of the communication strategy and
the smartphone-based tool in improving linkage and redu-
cing BP among hypertensive patients. This will be done
by conducting a three-arm cluster randomized controlled
trial comparing: 1) usual care (CHWs with standard train-
ing on recruitment of individuals with any chronic condi-
tion); 2) CHWs with a communication strategy; and
3) CHWs with the communication strategy and equipped
with smartphone technology. The co-primary outcome
measures will be: 1) documented linkage to care, and
2) one year change in systolic BP (SBP) among those with
hypertension. Third, we aim to evaluate the incremental
cost-effectiveness of each intervention arm of the cluster
randomized controlled trial, in terms of costs per unit




The United States Agency for International Development-
Academic Model Providing Access to Healthcare Partner-
ship (AMPATH) was initiated in Kenya in 2001 and has
established a HIV care system in western Kenya that
serves over 100,000 patients [24]. Based on that founda-
tion, and in partnership with the Government of Kenya,
AMPATH is expanding its clinical scope of work to in-
clude hypertension [25]. This study will be conducted
within the AMPATH infrastructure in western Kenya, in
the Kosirai and Turbo Divisions (Figure 1). Each Division
is geographically and administratively divided into Com-
munity Units of approximately 5,000 individuals, with 9
Figure 1 AMPATH centers in Kenya numbered 1 to 35 and lettered A to Z; Kosirai and Turbo Divisions highlighted.
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one rural health center staffed primarily by non-physician
clinical officers trained to deliver a range of clinical health
services [26], decentralized rural dispensaries staffed by
nurses, and CHWs who are assigned to specific units.
There has been a longstanding and positive relationship
among AMPATH, the healthcare providers, and these
communities [24,27,28]. The protocol has been approved
by the institutional review boards of all participating insti-
tutions (Additional file 1), and the study is a registered on
www.clinicaltrials.gov (identifier NCT01844596). Informed
consent will be obtained from all study participants using
a written informed consent form. During the consent
process, participants will have the opportunity to request
information and pose questions or concerns about their
participation in the study.
Conceptual framework
Many behavior change models have been developed that
focus on various types of health-related behavior and
disease entities. In this study, we use the Health Belief
Model, modified by incorporating the additional impact
of emotional and environmental factors on behavior
(Figure 2) [29]. The Health Belief Model is primarily a
cognitive model based on the domains of perceived risk,
perceived benefits, perceived barriers, cues to action,
and self-efficacy [30]. While the Health Belief Model
has been successfully applied to hypertension-related
research in a variety of settings and populations [31,32],we have expanded the model to incorporate the complex
interactions among cognition, emotion, environment, and
behavior. Emotional factors include desires, aspirations,
fears, and worries that may directly motivate action or
serve as a powerful lens to weigh advantages and disad-
vantages of alternative actions [33]. Environmental factors
include socioeconomic factors, costs, political constraints,
and cultural norms, which may facilitate or constrain an
individual’s behavior.
Facilitators and barriers to linkage and retention to
hypertension care
We will use a combination of qualitative research methods,
including traditional community assemblies (mabaraza)
and focus group discussions (FGDs), to identify the facilita-
tors and barriers to linkage and retention to hypertension
care. In East Africa, the mabaraza are used to address a
wide variety of situations, ranging from local disputes to
exchange of information. This unique and novel qualitative
research setting has been used as a form of participatory
action research related to HIV care [34]. The mabaraza
allow us to organize large and heterogeneous groups of in-
dividuals, which complement the purposive sampling in-
herent in FGDs.
For all qualitative sessions, we have developed moder-
ator guides, which have been used by trained moderators
fluent in the local languages. We have thus far con-
ducted 6 mabaraza and 17 FGDs using purposive sam-
pling by age, sex, occupation, and distance from nearest
Figure 2 Modified Health Belief Model: personal (cognitive and emotional) and environmental factors.
Vedanthan et al. Trials 2014, 15:143 Page 4 of 10
http://www.trialsjournal.com/content/15/1/143health facility. Participatory techniques have been used
to elicit emotional elements and promote group interac-
tions [35]. All sessions have been audio-recorded, tran-
scribed, and translated into English. Content analysis of
the transcripts will be performed using both deductive
(a priori) and inductive (emerging) codes [36]. The coded
items will be grouped together into distinct themes, and
relationships among these themes will be formulated.
Using the data gathered in the formative qualitative
sessions, we will use a participatory, iterative design
process to develop a tailored behavioral communication
strategy for CHWs to use as they interact with patients
and their families [37]. CHWs will be trained to engage
in practical, motivating, proactive problem-solving with
patients around such issues as transportation, clinic
scheduling, home responsibilities, stigma concerns, and
other issues that may be uncovered by the qualitative re-
search. We will develop both a hard copy version and a
smartphone version to be used by CHWs.
The smartphone version will be linked to the electronic
health record and will have two functionalities: 1) ability
to provide each CHW with an automatically updated list
of individuals requiring follow up; and 2) the ability to
provide real-time decision support based on the commu-
nication strategy, using data collected by the CHW during
a patient encounter. The decision support will use branch-
ing logic and decision trees based on specific motivationalmessages, as well as simple clinical care algorithms appro-
priate for CHWs. The smartphone technology will allow
for alternative messaging modalities, such as images and
recordings (both audio and visual).
Cluster randomized controlled trial
We will conduct a cluster randomized controlled trial
with three intervention arms: 1) usual care - CHWs with
standard training on recruitment of individuals with any
chronic condition (‘UC’); 2) CHWs with a tailored be-
havioral communication strategy (‘TBCS’); and 3) CHWs
with a communication strategy who are also equipped
with smartphone technology (‘TBCS-ST’). The unit of
randomization will be the community unit, since ran-
domization by CHW or patient would be at risk for con-
tamination, as all CHWs and nearly all patients within one
community unit are affiliated with the same dispensary.
Randomization will be stratified by division, so that the 9
units of Kosirai will be randomized separately from the 15
units of Turbo. The units will be randomly allocated to
one of the three intervention arms. The randomization
process will be conducted centrally by biostatisticians at
Brown University (Providence, United States). We will
compare key variables (such as age, sex, severity of
initial SBP, different treatment regimens, previous his-
tory of hypertension treatment, socioeconomic status,
body mass index, physical activity, alcohol consumption,
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ized groups, and make adjustments in our treatment effect
estimates as needed using logistic regression adjustment.
Study participants
Home-based BP testing using automatic BP machines
has been initiated by AMPATH in both the Kosirai and
Turbo divisions, with a plan to cover one-third of eachCHW-S = usual care
CHW-B = CHWs with an additional comm
CHW-BT = CHWs with a communication s
Figure 3 Classification of participants in trial. BP = Blood Pressure; CHW-S
arm; CHW-BT = communication strategy and smartphone technology arm; CUcommunity unit’s adult population every year. Inclusion
criteria for this study will be all adult individuals with el-
evated BP (SBP >140 or diastolic BP (DBP) >90) during
home-based testing, who will be assigned a unique med-
ical record number and referred to the local dispensary
for further evaluation (Figure 3). Exclusion criteria will
be individuals without elevated BP, those who are acutely
ill and require immediate medical attention at the timeunication strategy
trategy and with smartphone technology
= usual care arm; CHW-B = tailored behavioral communication strategy
- Community Unit.
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consent. Enrollment will occur for one year in each unit.
An individual who does not present to the dispensary
within one month will be defined as ‘non-linked’ and will
be identified by the dispensary nurse. At that point in
time, a CHW will be assigned to visit that individual to
encourage linkage to care. Those who do not link to care
within one month of the second CHW visit will be con-
sidered ‘chronic non-linked’. Individuals who ultimately
link to care will be characterized as ‘self-linked’ (linked
on their own without CHW intervention) or ‘CHW-
mediated linked’. At the dispensary, each individual who
has linked will have a repeat BP measured, and those
with repeat elevated BP will be entered into the hyperten-
sion management program as patients. Patients will be
managed according to the AMPATH hypertension proto-
col that is derived from consensus guidelines for hyper-
tension management, using drugs contained in the
Kenyan national formulary [38-40]. Patients who miss a
clinic appointment for more than one month will be con-
sidered ‘non-retained’. Patients who are retained in care
will be defined as either ‘self-retained’ (retained on
their own without CHW intervention) or ‘CHW-mediated
retained’. An individual will be considered ‘lost to follow
up’ if they does not return to the clinic for three months
despite CHW visits. The 12-month follow up BP will be
measured in the dispensary, in order to mimic real-world
practice.
Intervention and control
In the UC arm, the CHW will first measure the individual’s
BP. If it is elevated (SBP >140 or DBP >90), the CHW will
refer the individual to the dispensary for further evaluation
and management, as per the usual care protocol.
In the TBCS arm, the CHW will measure the individ-
ual’s BP and then will engage in behavioral, clinical, and
environmental assessments. Based on the behavioral as-
sessment, the CHW will employ the communication strat-
egy consisting of tailored behavioral and motivational
messages, as described above. Depending on the severity
of the clinical assessment, the CHW will either refer or ac-
company high-risk patients to the dispensary. The envir-
onmental assessment will evaluate socioeconomic barriers
to care-seeking, and the CHW will provide this informa-
tion to the nurses in the dispensary.
In the TBCS-ST arm, the CHW will conduct all assess-
ments described above; however, s/he will also be equipped
with a smartphone that has real-time decision support and
data entry that is linked to the electronic health record.
Thus, the smartphone will provide the tailored messaging
and specific recommendations based on inputs from the
assessments. The smartphone technology would allow for
alternative messaging modalities, such as images and re-
cordings (audio and visual), to ensure its applicability to apopulation speaking diverse languages and with different
literacy levels. If a patient does successfully go to the dis-
pensary for the linkage visit, this visit will be entered into
the electronic health record and we will program the sys-
tem to immediately send a positive reinforcement message
to the CHW.
Outcomes
The co-primary outcome measures will be: 1) docu-
mented linkage to care, defined as a confirmed dispens-
ary visit within one month of either home-based testing
(self-linked) or a CHW visit (CHW-mediated linked), and
2) one-year change in SBP among those with hyperten-
sion. Our ultimate goal is to implement an intention-to-
treat comparison of change in SBP among confirmed
hypertensive individuals. However, confirmation of hyper-
tensive status requires at least two BP measurements, and
this requires successful linkage to care (Figure 3). Hence,
we have opted for the co-primary outcome approach. We
will compare the proportion linked to care between the
three study arms using conditional logistic regression. For
the SBP outcome, we will implement an intention-to-treat
comparison of change in SBP between the three study
arms. For those who are not successfully linked to care,
we will use imputed SBP values. Full details of our ap-
proach to imputation appear in Additional file 2.
Statistical power
The study is powered on the linkage-to-care outcome in
order to preserve the properties of randomization at the
community unit level and avoid bias due to differential
selection into care by the linkage intervention. In light
of AMPATH’s pilot experience with home-based testing
and linkage to hypertension care [10], we anticipate that
the usual care arm will have 40% linkage (self-linked
plus CHW-mediated linked). The study is powered to
detect an absolute difference of 20% in percent linkage to
care between each of the three treatment arms (expected
60% linkage in the TBCS arm and 80% linkage in the
TBCS-ST arm). It is expected that 226 people will be re-
ferred to the dispensary per community unit per year,
based on the following: 1) each community unit has a
population of approximately 5,000; 2) 45.3% of the popula-
tion is above the age of 20 [41]; 3) one-third of the popula-
tion will be screened during the year; and 4) approximately
30% of adults will have an elevated SBP at the home-based
testing [10].
Our power calculations set overall Type I error rate at
5% (alpha = 0.05), and use a Bonferroni correction to per-
mit all pairwise comparisons between treatment arms. To
account for cluster effects, we consider scenarios where
intraclass correlation (ICC) ranges from 0 to 0.15 [42].
Plots demonstrating power for each of the pairwise treat-
ment arm comparisons across different values of ICC
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over a large range of ICC values (Figure 4).
Cost-effectiveness analysis
For each intervention arm, costs from the societal per-
spective will be captured using validated cost question-
naires and will include all relevant labor, materials,
supplies, and contracted services costs for all activities
required to deliver the interventions [43,44]. Only incre-
mental (variable and fixed) costs will be included in the
analysis. We will also identify which activities drive the
overall costs, and how costs would change if specific
activities are added or eliminated. We will also iden-
tify potential cost offsets (reductions in health services
utilization as a result of participation in a specific arm)
using health service utilization data contained within the
electronic health record and based on utilization and cost
questionnaires that participants will take at baseline andHorizontal line is at 80% power
UC = usual care
TBCS = CHWs with a tailored behavioral c
TBCS-ST = CHWs with a communication 
technology
Figure 4 Power to detect differences in the proportion of patients lin
line is at 80% power. CHWs, community health workers; ICC, intraclass corr
TBCS-ST, CHWs with a communication strategy and also equipped with sm12 months. We will thus quantify the net costs of partici-
pation in each intervention arm.
Once costs and effectiveness are calculated for each
intervention arm, we will then generate incremental cost-
effectiveness ratios (ICERs) following the approach de-
scribed in the literature [43]. First, costs and effectiveness
measures will be tabulated for each strategy in order of in-
creasing costs. After removing dominated interventions,
we will present the final ICERs and provide comparisons
to other CVD interventions and to other interventions
targeting this population after first converting the results
to international dollars using World Health Organization
conversion rates [45]. Our results will also be presented
in the form of cost-effectiveness acceptability curves [46],
which will show the probability that each strategy is
cost-effective for a range of monetary values that a decision-
maker might be willing to pay for a unit change in effective-
ness. In addition, we will perform one-way (and n-way)ommunication strategy
strategy and also equipped with smartphone 
ked to care over a realistic range of ICC coefficients. Horizontal
elation; TBCS, CHWs with a tailored behavioral communication strategy;
artphone technology; UC, usual care.
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changing one (or n) of the model parameters, holding all
other parameters constant.
We will evaluate the incremental cost-effectiveness of
each intervention arm, both in terms of costs per unit
decrease in BP and in terms of costs per unit reduction
in CVD risk by extrapolating one-year BP reductions to
CVD risk reductions based on the QRISK™2-2011 CVD
risk calculator (University of Nottingham, Nottingham,
United Kingdom) specific for Black African populations
[47]. We will then present costs per DALY saved by ex-
trapolating these reductions to all-cause mortality, using
an approach we have previously developed, with care to
note all assumptions required [48].
Discussion
The global burden of hypertension and other non-
communicable diseases is substantial and increasing,
especially in LMICs. However, insufficient data exist re-
garding effective health care delivery practices in these set-
tings. Each step in the implementation pathway, including
linkage and retention to care, can benefit from evidence-
based approaches. The LARK hypertension study has
been designed with these objectives in mind, and offers
several unique and innovative elements. First, we are
expanding the traditional Health Belief Model to include
emotional and environmental factors that influence health
behavior. Second, we are utilizing the mabaraza form of
qualitative inquiry and actively pursuing a participatory
methodology throughout all phases of the research. Third,
we are evaluating the use of mobile technology in a novel
domain of non-communicable disease care delivery. Fourth,
we are embedding the research within a foundational part-
nership of academic institutions, communities, and local
government, to ensure that the program meets the needs
of all stakeholder groups. Finally, we are working within
the existing structure of primary care delivery that is estab-
lished by the government.
We aim to demonstrate how the infrastructure and strat-
egies that have been established for the control of commu-
nicable diseases-including community-based screening,
task redistribution within teams, partnerships with local
providers, and medical informatics- can serve as a founda-
tion for an integrated delivery system approach to the con-
trol of non-communicable chronic conditions [49]. Thus,
the results of this project can serve as a platform to be
used for other non-communicable diseases, such as stroke,
diabetes, respiratory disease, cancer, and mental illness.
While this research is situated within a particular socio-
cultural and institutional context, we aim to produce
generalizable methods and results that can be applied in
other settings. We therefore hope that this project will pro-
vide a model for the evaluation of other new approaches to
non-communicable disease management in LMICs.Trial status
The cluster randomized controlled trial portion of this
study has not yet begun. The qualitative portion of the
study is currently ongoing.
Additional files
Additional file 1: Is the list of all IRBs that have approved the
protocol.
Additional file 2: Figure S1. Schematic illustrating the strategy for
estimating intention-to-treat effect on change in SBP among those
diagnosed with hypertension. Light gray boxes represent individuals with
suspected hypertension at time 0; white boxes represent patients with
hypertension; dark gray boxes represent those without hypertension.
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